Causes and frequency of blindness in patients with intraocular inflammatory disease.

Abstract

Aims/Background-Uveitis, an intraocular inflammatory disease, is a significant cause of visual impairment. It is not known how many patients with uveitis will retain visual acuity and how many develop visual impairment or even blindness. The aim of this study was to assess the frequency of blindness in patients with uveitis and, more specifically, to identify the clinical profile of patients at risk for visual loss. Methods-A cross sectional and retrospective study of 582 patients with uveitis who visited the ophthalmology departments of two university hospitals in the Netherlands was performed.

Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial

“…[1][2][3] Corticosteroids (CS) have been the mainstay of uveitis treatment, but ocular and/or systemic adverse effects limit their long-term use in the treatment of intermediate, posterior, or panuveitis. [4][5][6] The guidance from the Standardization of Uveitis Nomenclature (SUN) working group supports the use of systemic CS-sparing agents in patients on chronic CS treatment with quiescent disease; the ability to achieve a reduction in CS dose below a clinically meaningful threshold while maintaining inactive disease is a key determinant of treatment success.…”

Direct and indirect resource use, healthcare costs and work force absence in patients with non‐infectious intermediate, posterior or panuveitis

“…2013), NIIPPU is not particularly common; however, sight‐threatening complications, including macular oedema, glaucoma, visual disturbances and cataracts, are common in these patients (Rothova et al. 1996; Durrani et al. 2004a,b; Levin et al.…”

“…Non‐infectious uveitis may be idiopathic or associated with systemic autoimmune diseases (Rothova et al. 1996; Bodaghi et al. 2001; Chang & Wakefield 2002; Nguyen et al.…”

“…Regardless of the aetiology, persistent intra‐ocular inflammation can lead to structural ocular complications and visual disability (Rothova et al. 1996; Durrani et al. 2004a,b; Nguyen et al.…”

T cell–antigen-presenting cell interactions visualized in vivo in a model of antigen-specific inflammation

“…The iris is the potential target of T cell mediated inflammation which is known as iritis or anterior uveitis. Although uveitis or intraocular inflammation is a relatively rare disease, it ranks as one of the leading causes of blindness [12,13]. Anterior uveitis can occur in association with systemic inflammatory diseases such as ankylosing spondylitis, juvenile idiopathic arthritis, sarcoidosis, and Behçet's disease [14,15].…”